Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study.
Megumi KishimotoMayumi KomineKoji KamiyaJunichi SugaiAya KuwaharaMakiko Naka MienoMamitaro OhtsukiPublished in: Dermatology and therapy (2023)
Interleukin-17 inhibitors may be a favorable option for patients who need to switch from TNF inhibitors due to inadequate efficacy. However, this study is limited by the small number of cases and its retrospective design.
Keyphrases